Based on published clinical trials, we know that ICIs targeting the PD-1/PD-L1 pathway have a beneficial effect on the treatment of patients with advanced or metastatic cancer compared to conventional therapy4. This evidence concerns the gene CD274 and metastatic malignant neoplasm.